利妥昔单抗联合改良CHOP方案治疗非霍奇金淋巴瘤的临床疗效  

Clinical efficacy of rituximab combined modified CHOP regimen in the treatment of non-Hodgkin lymphoma

作　　者：杨波 岳恺[1] 朱晓果 YANG Bo;YUE Kai;ZHU Xiaoguo(Department of Medical Oncology,Nanyang Central Hospital,Nanyang 473000,He’nan,China)

机构地区：[1]南阳市中心医院肿瘤内科,河南南阳473000

出　　处：《癌症进展》2023年第6期656-659,共4页Oncology Progress

摘　　要：目的探讨利妥昔单抗联合改良环磷酰胺+泼尼松+长春新碱+多柔比星(CHOP)方案治疗非霍奇金淋巴瘤的临床疗效。方法根据治疗方式的不同将150例非霍奇金淋巴瘤患者分为对照组和观察组,每组75例,对照组患者给予改良CHOP方案治疗,观察组患者在对照组的基础上给予利妥昔单抗治疗,两组患者均予以综合干预。比较两组患者的临床疗效、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQC30)]及不良反应发生情况。结果观察组患者的总有效率为85.33%,高于对照组患者的68.00%(P﹤0.05)。治疗后,两组患者躯体功能、情绪功能、社会功能、认知功能、角色功能评分均高于本组治疗前,且观察组患者躯体功能、情绪功能、社会功能、认知功能、角色功能评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论利妥昔单抗联合改良CHOP方案治疗非霍奇金淋巴瘤患者能够提高临床疗效及生活质量,且安全有效。Objective To investigate the clinical efficacy of rituximab combined modified cyclophosphamide+prednisone+vincristine+doxorubicin(CHOP)regimen in the treatment of non-Hodgkin lymphoma.Method A total of 150 patients with non-Hodgkin lymphoma were divided into control group(n=75,treated with modified CHOP regimen)and observation group(n=75,treated with modified CHOP regimen+rituximab)according to different treatment methods,and both groups received comprehensive intervention.The clinical efficacy,quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)]and incidence of adverse reactions were compared between the two groups.Result The clinical effective rate of the observation group was 85.33%,higher than 68.00%of the control group(P<0.05).After treatment,the scores of physical function,emotional function,social function,cognitive function and role function in the two groups were higher than those before treatment,with higher scores in the observation group than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rituximab combined modified CHOP regimen in the treatment of non-Hodgkin lymphoma can improve the clinical efficacy and quality of life of patients,which is safe and effective.

关 键 词：非霍奇金淋巴瘤 利妥昔单抗 改良CHOP方案 临床疗效 

分 类 号：R733.4[医药卫生—肿瘤]